logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
delete
arrow
返回
L

Lawrence Liberti

Temple University

18H指数
57论文数
991被引数
收录论文 18
发表时间
logo
The FDA’s Pivotal Role in Global Therapeutic Product AvailabilityFDA在全球治疗产品可及性中的关键作用
errClinical Therapeutics
IF3.6
err2025-05-15
err0
PREAI
errLawrence Liberti; Eunjoo Pacifici
err分享
err收藏
Cooperation Agreements, Memorandums of Understanding, and Letters of Intent as Instruments to Facilitate the Implementation of Reliance in Latin America
errCLINICAL THERAPEUTICS
IF3.6
err2022-08-01
err2
errOAAI
errRodriguez, Heraclio; De Lucia, Maria Lucia; Liberti, Lawrence
err分享
err收藏
Transparency in European Medicines Agency and US Food and Drug Administration Decision Making: Is It Possible to Identify the Rationale for Divergences in Approved Indication From Public Assessment Reports?欧洲药品管理局和美国食品和药物管理局决策的透明度: 是否有可能从公共评估报告中识别出已批准适应症的差异的理由？
errCLINICAL THERAPEUTICS
IF3.6
err2021-05-01
err4
errOAAI
errBujar, Magda; Ferragu, Sara; McAuslane, Neil; Liberti, Lawrence; Kuhler, Thomas C.
err分享
err收藏
The Qualitative Value of Facilitated Regulatory Pathways in Europe, USA, and Japan: Benefits, Barriers to Utilization, and Suggested Solutions
errPHARMACEUTICAL MEDICINE
IF4.5
err2021-02-04
err5
errOAAI
errBujar, Magdalena; McAuslane, Neil; Liberti, Lawrence
err分享
err收藏
An evaluation of the Caribbean regulatory system centralized assessment process for medicines submitted 2017-2018 using the OpERA methodology
errJOURNAL OF PHARMACEUTICAL POLICY AND PRACTICE
IF2.5
err2020-09-08
err2
errOAAI
errLiberti, Lawrence; Extavour, Rian Marie; Patel, Prisha; McAuslane, Neil
err分享
err收藏
The Confluence of Accelerated Regulatory and Health Technology Assessment Access Pathways
errCLINICAL PHARMACOLOGY & THERAPEUTICS
IF5.5
err2019-01-16
err10
PREAI
errMcAuslane, Neil; Liberti, Lawrence; Connelly, Patricia
err分享
err收藏
TIME TO HTA DECISION FOR INTERNATIONALISED MEDICINES IN AUSTRALIA, CANADA AND EUROPE
errVALUE IN HEALTH
IF6
err2018-10-01
err0
errOAAI
errCai, J.; McAuslane, N.; Liberti, L.
err分享
err收藏
Building Synergy between Regulatory and HTA Agencies beyond Processes and Procedures-Can We Effectively Align the Evidentiary Requirements? A Survey of Stakeholder Perceptions
errVALUE IN HEALTH
IF6
err2018-06-01
err37
errOAAI
errWang, Ting; McAuslane, Neil; Liberti, Lawrence; Leufkens, Hubert; Hovels, Anke
err分享
err收藏
Accelerated approval of medicines: fit for purpose?
errNATURE REVIEWS DRUG DISCOVERY
IF101.8
err2018-01-05
err3
PREAI
errBreckenridge, Alasdair; Liberti, Lawrence
err分享
err收藏
Factors related to drug approvals: predictors of outcome?
errDRUG DISCOVERY TODAY
IF7.5
err2017-06-01
err8
errOAAI
errLiberti, Lawrence; Breckenridge, Alasdair; Hoekman, Jarno; McAuslane, Neil; Stolk, Pieter; Leufkens, Hubert
err分享
err收藏
Health Technology Assessment (HTA) Case Studies: Factors Influencing Divergent HTA Reimbursement Recommendations in Australia, Canada, England, and Scotland
errVALUE IN HEALTH
IF6
err2017-03-01
err57
errOAAI
errAllen, Nicola; Walker, Stuart R.; Liberti, Lawrence; Salek, Sam
err分享
err收藏
Structured Frameworks to Increase the Transparency of the Assessment of Benefits and Risks of Medicines: Current Status and Possible Future Directions
errCLINICAL PHARMACOLOGY & THERAPEUTICS
IF5.5
err2015-09-11
err36
errOAAI
errPignatti, F.; Ashby, D.; Brass, E. P.; Eichler, H-G; Frey, P.; Hillege, H. L.; Hori, A.; Levitan, B.; Liberti, L.; Loefstedt, R. E.; McAuslane, N.; Micaleff, A.; Noel, R. A.; Postmus, D.; Renn, O.; Sabourin, B. J.; Salmonson, T.; Walker, S.
err分享
err收藏
Adaptive Licensing and Facilitated Regulatory Pathways: A Survey of Stakeholder Perceptions
errCLINICAL PHARMACOLOGY & THERAPEUTICS
IF5.5
err2015-06-30
err14
PREAI
errLiberti, L.; Stolk, P.; McAuslane, N.; Somauroo, A.; Breckenridge, A. M.; Leufkens, H. G. M.
err分享
err收藏
DO HTA PROCESSES CORRELATE WITH REIMBURSEMENT RECOMMENDATIONS?
errVALUE IN HEALTH
IF6
err2014-11-01
err2
errOAAI
errAllen, N.; Lipska, I; Liberti, L.; Salek, M. S.
err分享
err收藏
Regulatory Review: How Do Agencies Ensure the Quality of Decision Making?
errCLINICAL PHARMACOLOGY & THERAPEUTICS
IF5.5
err2013-09-01
err7
PREAI
errLiberti, L.; McAuslane, N.; Patel, P.; Breckenridge, A.; Eichler, H. G.; Peterson, R.
err分享
err收藏
Refining the Benefit-Risk Framework for the Assessment of Medicines: Valuing and Weighting Benefit and Risk Parameters
errCLINICAL PHARMACOLOGY & THERAPEUTICS
IF5.5
err2011-02-01
err21
PREAI
errWalker, S.; Liberti, L.; McAuslane, N.
err分享
err收藏
Expediting Patients' Access to Medicines by Improving the Predictability of Drug Development and the Regulatory Approval Process
errCLINICAL PHARMACOLOGY & THERAPEUTICS
IF5.5
err2010-01-01
err11
PREAI
errLiberti, L.; Breckenridge, A.; Eichler, H. G.; Peterson, R.; McAuslane, N.; Walker, S.
err分享
err收藏
Measuring Benefit and Balancing Risk: Strategies for the Benefit-Risk Assessment of New Medicines in a Risk-Averse Environment
errCLINICAL PHARMACOLOGY & THERAPEUTICS
IF5.5
err2009-03-01
err19
PREAI
errWalker, S.; McAuslane, N.; Liberti, L.; Salek, S.
err分享
err收藏

研究方向

暂时未获取到该数据
合作学者
合作期刊
O
Ortwin Renn
H 指数: 78 · 论文数: 733
D
Deborah Ashby
H 指数: 73 · 论文数: 324
H
Hubert G. M. Leufkens
H 指数: 72 · 论文数: 509
P
Pascal Frey
H 指数: 65 · 论文数: 566
S
Sam Salek
H 指数: 47 · 论文数: 411
查看更多